Bromodomain Inhibition Overcomes Treatment Resistance in Distinct Molecular Subtypes of Melanoma

Scientists developed a therapeutic strategy for melanoma using bromosporine, a bromodomain inhibitor. Bromosporine monotherapy produced significant anti-tumor effects against established melanoma cell lines and patient-derived xenografts.